-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Brilacidin is a new research drug, a polymer-based antibiotic that represents a new class of antibiotics, called host defense protein simulators or HDP analogs, that mimic non-peptide-synthetic small molecules of host defense peptides.
HDP (also known as antimicrobial peptides) is part of the innate immune response.
biopharmaceutical company Innovation reported today that ongoing in vitro trials support Brilacidin as a potential treatment for COVID-19.
, chief executive of Innovation Pharmaceuticals, said: "The latest Brilacidin in-body efficacy is excellent.
Selectivity Index (SI) is the most important indicator of the antiviral efficacy of many experimental drugs, and this new data shows that Blaclacdin has significant anti-SARS-CoV-2 activity, indicating that Brilacidin has great potential for the treatment of COVID-19".
the vast majority of COVID-19 therapies are below Brilacidin, according to publicly available information.
based on a recent screening of 5,632 compounds (), only 19 were identified as having anti-SARS-CoV-2 activity, with Brilacidin among them.
Brilacidin showed strong in-body resistance to SARS-CoV-2 at low concentrations, well below the effective concentrations in Brilacidin's treatment of acute bacterial skin and skin structure infections.
.